|
|
|
Volumn 26, Issue 6, 1999, Pages 589-605
|
|
Where do we stand with 5-fluorouracil?
a
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
DIPYRIDAMOLE;
FLUOROURACIL;
FOLINIC ACID;
INTERFERON;
IRINOTECAN;
LEVAMISOLE;
METHOTREXATE;
MITOMYCIN;
OXALIPLATIN;
RALTITREXED;
SPARFOSIC ACID;
TRIMETREXATE;
ZIDOVUDINE;
ANTINEOPLASTIC ACTIVITY;
ARTICLE;
CANCER COMBINATION CHEMOTHERAPY;
CANCER RADIOTHERAPY;
CANCER SURVIVAL;
CHRONOTHERAPY;
CLINICAL PROTOCOL;
COLORECTAL CANCER;
DRUG EFFICACY;
DRUG METABOLISM;
DRUG POTENTIATION;
GENE THERAPY;
HUMAN;
PRIORITY JOURNAL;
RADIOSENSITIZATION;
RECTUM CANCER;
TREATMENT OUTCOME;
ANTIMETABOLITES, ANTINEOPLASTIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
ASPARTIC ACID;
CHRONOTHERAPY;
COLORECTAL NEOPLASMS;
DIPYRIDAMOLE;
DRUG SYNERGISM;
FLUOROURACIL;
HUMANS;
INTERFERONS;
LEUCOVORIN;
LEVAMISOLE;
METHOTREXATE;
PHOSPHONOACETIC ACID;
RADIATION-SENSITIZING AGENTS;
TRIMETREXATE;
ZIDOVUDINE;
|
|
EID: 0033388866
PISSN: 00937754
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (97)
|
|
References (113)
|
